#OpenAI

OpenAI's quiet reversal of a key ChatGPT feature reveals a critical truth: speed is beating raw intelligence in the AI race. Our analysis on why this is a major win for Google.

OpenAI's AI for biology is more than a paper. It's a strategic play to upend the multi-trillion dollar pharma industry. Here's our expert analysis.

OpenAI's FrontierScience benchmark signals a strategic pivot from chatbots to automating scientific discovery. A deep dive into why this changes the game for R&D and tech investors.

BBVA's deal to deploy ChatGPT to 120,000 staff is more than a tech upgrade. Our analysis shows it's a strategic gambit to become the world's first AI-native bank.

BNY Mellon is arming 20,000 employees to build custom AI agents. This is more than a tech upgrade—it's a strategic revolution that redefines the enterprise AI playbook.

Chai Discovery's $1.3B valuation, backed by OpenAI, isn't just a funding round. It's a signal that AI is set to industrialize drug creation, challenging Big Pharma's core model.

OpenAI's new GPT-Image-1.5 model is more than a speed upgrade. It's a strategic move to dominate the enterprise AI space. Our analysis explains why.

OpenAI's quiet GPT-5.2 update isn't what it seems. Discover why this 'silent upgrade' signals a major strategic shift in the AI wars and what it means for investors.

OpenAI's GPT-5.2 isn't just an update; its mastery of math and science marks a foundational shift for AI, unlocking a new era of automated R&D.

OpenAI shipped Sora for Android in 28 days using AI. Our analysis breaks down how this signals a new era of AI-first software development and what it means for the industry.

BNY is arming 20,000 employees with OpenAI. This isn't just about efficiency—it's a new blueprint for enterprise AI that will create a new class of winners and losers.

Chai Discovery's $130M raise at a $1.3B valuation isn't about a single drug. It's a strategic move by OpenAI's ecosystem to build the dominant AI platform for biotech.